Grimm, Nina-Antonia http://orcid.org/0000-0002-8639-2046
Fahimi, Sarah
Kück, Fabian
Take, Patricia
Lauermann, Peer
Nguyen-Hoehl, Anna
Hoerauf, Hans
Feltgen, Nicolas
Bemme, Sebastian
Funding for this research was provided by:
Georg-August-Universität Göttingen
Article History
Received: 22 November 2022
Revised: 22 January 2023
Accepted: 31 January 2023
First Online: 16 March 2023
Declarations
:
: This study concurs with the 1964 Helsinki declaration and its later amendments, and was approved by our institutional ethics committee of the university of Goettingen (application number is 6/11/20).
: Nina-Antonia Grimm: Speaker: Novartis AG, Bayer AG, OD-OS GmbH.Sarah Fahimi: No conflict of interest.Fabian Kück: No conflict of interest.Patricia Take: No conflict of interest.Peer Lauermann: No conflict of interest.Anna Nguyen-Hoehl: No conflict of interest.Hans Hoerauf: Consultant: Novartis, Roche Allergan; Speaker: Novartis, Roche, Allergan, Biogen, Alcon, Heidelberg Engeneering; Research projects: Bayer Heath Care, Novartis, Allergan, chengdu Khanghong, Biotec, Hoffmann LaRoche, Samsung, Benevolent, Regeneron, Santen GmbH, Boehringer Ingelheim, Mylan, Appelis; Owner interest in medical products: Novartis, Bayer, 3 M, Roche, Johnson&Johnson, Mediatronis, Abbvie, Pfizer.Nicolas Feltgen: Consultant: Alimera Sciences, Novartis, Roche; Speaker: Allergan, Alimera, Bayer, Heidelberg Engineering, Novartis, Roche.Sebastian Bemme: Speaker: Novartis AG, Bayer AG; Research grant: Novartis AG.